Response Biomedical Expands Global Diagnostics Portfolio with the Launch of the RAMP Xpress (opens original article in a new tab)

Response Biomedical expands its diagnostics portfolio with the RAMP Xpress, a platform for metabolic and inflammatory biomarker testing, receiving regulatory approvals and aiming to improve access to rapid diagnostic solutions.

• Response Biomedical launches RAMP Xpress, a diagnostic platform for metabolic and inflammatory biomarkers
• RAMP Xpress receives Class II medical device licenses from Health Canada and is being registered internationally
• The platform offers four quantitative assays and is designed for flexibility, speed, and lab-quality standards
• Response plans to develop new tests and expand access to diagnostics in cost-prohibitive markets